In 27,870 adults on basal insulin, a glucose sensor tracked a 44% lower risk of death at one year

What the research found

Study (observational). Jochen Seufert of the University Hospital of Freiburg and colleagues, using the Truveta records platform, compared adults with type 2 diabetes on basal insulin who filled a first continuous glucose monitor prescription with matched adults who did not (EASD, Milan; Medical Xpress 27 September 2026). Each group had 13,935 people, matched on 29 characteristics including age, sex, diabetes duration, complications, HbA1c, other illnesses, medicines, and how often they used care. Average age was 58, and 47% were women. Records ran from 1 January 2017 to 18 March 2024. At 12 months, death from any cause occurred in 1.16% of sensor users and 2.09% of non-users, a 44% lower risk. At 24 months the risk was 35% lower (2.12% versus 3.26%). A new macrovascular event — heart attack, heart failure, stroke, transient ischemic attack, or peripheral artery disease — was 26% less common at 12 months (1.03% versus 1.39%) and 24% less common at 24 months. Recurrent events were 35% and 36% lower at those two points. Heart-failure hospitalizations were 54% lower at 12 months and 47% lower at 24 months. The authors say this cannot prove the sensor caused the difference, because unmeasured differences can remain, and later medicine changes were not tracked. It is not advice to start or change insulin. Educational notes.

Evidence level: Human study. A study in people, but an association isn't proof of cause.

Read the original at University Hospital of Freiburg / EASD via Medical Xpress